Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Inadvertent Intrathecal Administration of Vincristine.

View through CrossRef
Abstract Background: Vincristine is a vesicant drug which is normally given intravenously. Intrathecal administration of vincristine is a therapeutic misadventure, causing chemical leptomeningitis and focal ventriculitis. While 55 cases of intrathecal vincristine administration have been reported worldwide, only 32 cases have been documented in the literature, 13 have been reported to the FDA Med Watch, and many more cases are believed to be unreported. Of the documented cases, 84.3% resulted in death and 15.6% of those who survived had serious neurological consequences such as quadriplegia and paraplegia. Methods: The Research on Adverse Events and Reports (RADAR) project conducted a review of literature published between 1968 and June 2006. Sources included Med Watch reports, published abstracts and journal articles, online newsletters, and letters from pharmacists. Findings: The reports reviewed showed that intrathecal administration of vincristine occurred most often because of inadequate communication between pharmacy and medical staff (22 of 32 cases; 68.7%). In these cases, the pharmacy mistakenly delivered vincristine syringes together with syringes containing intrathecal medications and physicians or nurses wrongly administered vincristine intrathecally. Pharmacy error alone, such as the mislabeling of syringes, accounted for 6 of 32 cases of intrathecal administration of vincristine (18.7%) while physician/nurse error alone (failure to read syringe labeling or check physician’s orders) accounted for 4 of 32 cases (12.5%). Conclusions: Since vincristine is lethal when given intrathecally, its administration should be executed with the precautionary measures employed with other potentially lethal substances, such as blood products. Carefully reviewing physician orders before drug administration and dispensing vincristine in syringes incompatible with spinal needles can also curb fatal error. Other preventive measures include properly labeling vincristine syringes for intravenous use only and diluting vincristine in intravenous mini-infusion bags. Literature review of case reports since 1968 < 1985 1986–1990 1991–1995 1996–2000 2001–2005 Total USA/Canada 7 1 2 4 2 16 Europe 0 0 2 2 1 5 Australia 0 1 1 0 1 3 Asia 1 0 1 3 0 5 Total Cases 8 2 6 8 8 32 Deaths 8 1 4 6 8 27 (84.3%) Pharmacy/medical staff error 5 1 3 5 5 22 (68.7%) Pharmacy error 2 0 2 2 3 6 (18.7%) Physician/Nurse error 1 1 1 1 0 4 (12.5%)
Title: Inadvertent Intrathecal Administration of Vincristine.
Description:
Abstract Background: Vincristine is a vesicant drug which is normally given intravenously.
Intrathecal administration of vincristine is a therapeutic misadventure, causing chemical leptomeningitis and focal ventriculitis.
While 55 cases of intrathecal vincristine administration have been reported worldwide, only 32 cases have been documented in the literature, 13 have been reported to the FDA Med Watch, and many more cases are believed to be unreported.
Of the documented cases, 84.
3% resulted in death and 15.
6% of those who survived had serious neurological consequences such as quadriplegia and paraplegia.
Methods: The Research on Adverse Events and Reports (RADAR) project conducted a review of literature published between 1968 and June 2006.
Sources included Med Watch reports, published abstracts and journal articles, online newsletters, and letters from pharmacists.
Findings: The reports reviewed showed that intrathecal administration of vincristine occurred most often because of inadequate communication between pharmacy and medical staff (22 of 32 cases; 68.
7%).
In these cases, the pharmacy mistakenly delivered vincristine syringes together with syringes containing intrathecal medications and physicians or nurses wrongly administered vincristine intrathecally.
Pharmacy error alone, such as the mislabeling of syringes, accounted for 6 of 32 cases of intrathecal administration of vincristine (18.
7%) while physician/nurse error alone (failure to read syringe labeling or check physician’s orders) accounted for 4 of 32 cases (12.
5%).
Conclusions: Since vincristine is lethal when given intrathecally, its administration should be executed with the precautionary measures employed with other potentially lethal substances, such as blood products.
Carefully reviewing physician orders before drug administration and dispensing vincristine in syringes incompatible with spinal needles can also curb fatal error.
Other preventive measures include properly labeling vincristine syringes for intravenous use only and diluting vincristine in intravenous mini-infusion bags.
Literature review of case reports since 1968 < 1985 1986–1990 1991–1995 1996–2000 2001–2005 Total USA/Canada 7 1 2 4 2 16 Europe 0 0 2 2 1 5 Australia 0 1 1 0 1 3 Asia 1 0 1 3 0 5 Total Cases 8 2 6 8 8 32 Deaths 8 1 4 6 8 27 (84.
3%) Pharmacy/medical staff error 5 1 3 5 5 22 (68.
7%) Pharmacy error 2 0 2 2 3 6 (18.
7%) Physician/Nurse error 1 1 1 1 0 4 (12.
5%).

Related Results

Chinese Herbs of Shenghe Powder Reverse Multidrug Resistance of Gastric Carcinoma SGC-7901
Chinese Herbs of Shenghe Powder Reverse Multidrug Resistance of Gastric Carcinoma SGC-7901
The objective of this study was to investigate the reversal effect of Chinese herbs of Shenghe Powder on the multidrug resistance of the human SGC-7901 gastric carcinoma cell line ...
Effect of repeated vincristine administration on platelet count in cats with lymphoma
Effect of repeated vincristine administration on platelet count in cats with lymphoma
Abstract Background Vincristine is a chemotherapy drug used to treat haemopoietic tumours such as lymphomas. In healthy d...
Awareness about Intrathecal Drug Administration among Dental students
Awareness about Intrathecal Drug Administration among Dental students
Intrathecal administration includes the immediate infusion of the medication in Cerebro Spinal Fluid(CSF) internal to the intrathecal space of the spinal column. The intrathecal co...
Vincristine‐induced unilateral ptosis
Vincristine‐induced unilateral ptosis
AbstractPurpose To report the ocurrence of an unilateral ptosis in a 2‐year‐old girl treated by vincristine for a vaginal rhabdomyosarcoma.Methods Our young patient developed a vag...
Vincristine-Induced Neuropathy in Patients Diagnosed with Solid and Hematological Malignancies: The Role of Dose Rounding
Vincristine-Induced Neuropathy in Patients Diagnosed with Solid and Hematological Malignancies: The Role of Dose Rounding
Background: Vincristine is a vital constituent of chemotherapeutic regimens. Vincristine-induced neuropathy is a challenging adverse effect that impacts quality of life and treatme...
Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice
Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice
Among the vinca-alkaloid class, vincristine is a potent chemotherapeutic agent with significant neurotoxic effects and is employed to address a wide spectrum of cancer types. Recen...
Unlocking the Intrathecal Route: A Comprehensive Review
Unlocking the Intrathecal Route: A Comprehensive Review
The intrathecal route of administration, which involves the direct delivery of therapeutic agents into the cerebrospinal fluid (CSF) via lumbar or cervical puncture, has gained inc...
Intrathecal Dexmedetomidine Attenuates Hypercapnic but Not Hypoxic Cerebral Vasodilation in Anesthetized Rabbits
Intrathecal Dexmedetomidine Attenuates Hypercapnic but Not Hypoxic Cerebral Vasodilation in Anesthetized Rabbits
Background Systemic dexmedetomidine (DXM) attenuates the cerebral vasodilation induced by hypercapnia and decreases the cerebral blood flow response to hypoxia. We dete...

Back to Top